Taysha Gene Therapies Earnings Call Transcripts
Fiscal Year 2026
-
TSHA-102 clinical and regulatory progress continued, with pivotal trial dosing on track for Q2 2026 and strong FDA alignment on BLA submission scenarios. Financials reflect increased R&D investment, and market research shows high demand for gene therapy with preference for intrathecal delivery.
Fiscal Year 2025
-
Significant clinical, regulatory, and commercial progress was made in 2025, highlighted by positive TSHA-102 data, FDA Breakthrough Therapy designation, and strong financial positioning with $319.8M in cash. Pivotal and ASPIRE trials are on track, with commercial readiness advancing.
-
FDA breakthrough therapy designation and regulatory alignment position TSHA-102 for accelerated pivotal trial execution and BLA submission. Strong clinical data, regained global rights, and a solid cash position support late-stage development and commercialization.
-
Pivotal trial for TSHA-102 in Rett Syndrome is underway with strong efficacy and safety data, 100% response rate in Part A, and regulatory alignment. Financial position is robust with $312.8M in cash and a runway into 2028, following a $230M capital raise.
-
Significant regulatory and clinical progress was made for the Taysha 102 Rett syndrome program, with FDA alignment on pivotal trial design and strong safety and efficacy signals in early trials. Cash runway extends into Q4 2026, and pivotal trial initiation is expected soon.
Fiscal Year 2024
-
Dosing in both Phase II Reveal trials for TSHA-102 in Rett syndrome is complete, with no treatment-related SAEs or DLTs and encouraging functional gains observed. Financials show improved net loss and a cash runway into Q4 2026. Key regulatory and clinical updates are expected in the first half of 2025.
-
TSHA-102 gene therapy for Rett syndrome advanced with strong safety, early efficacy, and regulatory progress, including FDA RMAT designation and pivotal product approval. Financials show improved net loss and a cash runway into Q4 2026.
-
TSHA-102 clinical trials for Rett syndrome showed encouraging safety and efficacy in both low- and high-dose cohorts, with improvements across key clinical domains. Financially, reduced net loss and a $76.8M capital raise extended cash runway into Q4 2026.
-
Positive interim data from TSHA-102 trials in Rett syndrome show sustained, multi-domain improvements in both adults and children with diverse genetic backgrounds. No serious adverse events related to treatment were observed, and dose escalation is underway.